Compare Citius Pharmaceuticals Inc (CTXR) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while Alliant Energy Corporation trades at $70.18 (market cap $17.78B). The key difference: Alliant Energy Corporation is far larger — about 888.6× Citius Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.12% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LNT | |
|---|---|---|
Market Cap | $20.01M | $17.78B |
Sector | Health | Utilities |
52-Week High | $1.82 | $78.03 |
52-Week Low | $0.48 | $63.62 |
Enterprise Value | $16.23M | $29.88B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Alliant Energy (LNT) trades at $70.01, up 2.64% today. The stock shows a bearish technical trend with support at $67-$68 and resistance at $69-$70. Fundamentally, the company reported strong Q2 2026 earnings of $0.65 per share, beating estimates, and maintains solid profitability with an 18.45% net income margin. Analyst consensus is a 'Buy' with a $77.67 price target, implying 11% upside. Recent news highlights institutional buying and dividend stability.
LNT offers a stable investment with consistent earnings growth and a reliable dividend, but faces risks from rising debt levels and regulatory pressures. The stock's current valuation at a P/E of 21.7 is reasonable for a utility, supporting a cautious bullish outlook amid technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
